(Q53450365)

English

ERCC1 (excision repair cross-complementation group 1) expression as a predictor for response of neoadjuvant chemotherapy for FIGO stage 2B uterine cervix cancer.

scientific article published on 19 November 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/21093896

ERCC1 (excision repair cross-complementation group 1) expression as a predictor for response of neoadjuvant chemotherapy for FIGO stage 2B uterine cervix cancer. (English)

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/21093896

1 reference

based on heuristic

inferred from title

author name string

Jong-Sup Park

1

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/21093896

Eun Kyung Jeon

2

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/21093896

Sang Hoon Chun

3

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/21093896

Hye Seong Won

4

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/21093896

Ahwon Lee

5

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/21093896

Soo Young Hur

6

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/21093896

Keun Ho Lee

7

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/21093896

Seog-Nyeon Bae

8

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/21093896

Sei-Chul Yoon

9

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/21093896

Sook Hee Hong

10

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/21093896

language of work or name

0 references

publication date

19 November 2010

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/21093896

Gynecologic Oncology

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/21093896

120

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/21093896

2

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/21093896

275-279

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/21093896

Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.10.034

7 January 2021

Radical hysterectomy for stage IIB cervical cancer: a review

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.10.034

7 January 2021

The current role of neoadjuvant chemotherapy in the management of cervical carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.10.034

7 January 2021

Neoadjuvant chemotherapy and radical surgery versus exclusive radiotherapy in locally advanced squamous cell cervical cancer: results from the Italian multicenter randomized study.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.10.034

7 January 2021

Randomized trial of neoadjuvant chemotherapy comparing paclitaxel, ifosfamide, and cisplatin with ifosfamide and cisplatin followed by radical surgery in patients with locally advanced squamous cell cervical carcinoma: the SNAP01 (Studio Neo-Adjuvan

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.10.034

7 January 2021

A phase II, randomized trial of neo-adjuvant chemotherapy comparing a three-drug combination of paclitaxel, ifosfamide, and cisplatin (TIP) versus paclitaxel and cisplatin (TP) followed by radical surgery in patients with locally advanced squamous c

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.10.034

7 January 2021

Long-term follow-up of the first randomized trial using neoadjuvant chemotherapy in stage Ib squamous carcinoma of the cervix: the final results

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.10.034

7 January 2021

Cis-platinum in treatment of advanced or recurrent squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.10.034

7 January 2021

DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.10.034

7 January 2021

Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.10.034

7 January 2021

Mechanisms of DNA excision repair

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.10.034

7 January 2021

Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.10.034

7 January 2021

ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.10.034

7 January 2021

Neoadjuvant cisplatin and etoposide followed by radical hysterectomy for stage 1B-2B cervical cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.10.034

7 January 2021

Defining the roles of nucleotide excision repair and recombination in the repair of DNA interstrand cross-links in mammalian cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.10.034

7 January 2021

The structure-specific endonuclease Ercc1-Xpf is required to resolve DNA interstrand cross-link-induced double-strand breaks

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.10.034

7 January 2021

Prognostic significance of p-STAT3 in patients with bulky cervical carcinoma undergoing neoadjuvant chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.10.034

7 January 2021

Prognostic significance of VEGF expression in patients with bulky cervical carcinoma undergoing neoadjuvant chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.10.034

7 January 2021

CD44 isoform 6 (CD44v6) is a prognostic indicator of the response to neoadjuvant chemotherapy in cervical carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.10.034

7 January 2021

Chemosensitivity correlation between the primary tumors and simultaneous metastatic lymph nodes of patients evaluated by DNA synthesis inhibition assay

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.10.034

7 January 2021

Identifiers

10.1016/J.YGYNO.2010.10.034

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/21093896

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/21093896

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53450365&oldid=1372445310"